ORY Stock Overview
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Oryzon Genomics S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €1.71 |
52 Week High | €2.43 |
52 Week Low | €1.55 |
Beta | 0.67 |
1 Month Change | -8.26% |
3 Month Change | -12.76% |
1 Year Change | -22.27% |
3 Year Change | -52.70% |
5 Year Change | -51.90% |
Change since IPO | -62.83% |
Recent News & Updates
Recent updates
Oryzon Genomics S.A. (BME:ORY) Screens Well But There Might Be A Catch
Jun 09Is Oryzon Genomics (BME:ORY) Using Too Much Debt?
Apr 04Industry Analysts Just Made A Dazzling Upgrade To Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts
Jul 24Is Oryzon Genomics (BME:ORY) Weighed On By Its Debt Load?
May 01Oryzon Genomics (BME:ORY) Has Debt But No Earnings; Should You Worry?
Feb 26If You Had Bought Oryzon Genomics (BME:ORY) Shares A Year Ago You'd Have Earned 18% Returns
Jan 04Shareholder Returns
ORY | ES Biotechs | ES Market | |
---|---|---|---|
7D | -1.8% | 6.1% | 2.2% |
1Y | -22.3% | -11.1% | 18.8% |
Return vs Industry: ORY underperformed the Spanish Biotechs industry which returned -11.1% over the past year.
Return vs Market: ORY underperformed the Spanish Market which returned 18.8% over the past year.
Price Volatility
ORY volatility | |
---|---|
ORY Average Weekly Movement | 5.7% |
Biotechs Industry Average Movement | 7.4% |
Market Average Movement | 3.2% |
10% most volatile stocks in ES Market | 6.6% |
10% least volatile stocks in ES Market | 0.7% |
Stable Share Price: ORY's share price has been volatile over the past 3 months.
Volatility Over Time: ORY's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Spanish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 43 | Carlos Manuel Arjol | https://www.oryzon.com |
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases.
Oryzon Genomics S.A. Fundamentals Summary
ORY fundamental statistics | |
---|---|
Market cap | €98.52m |
Earnings (TTM) | -€3.42m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-28.8x
P/E RatioIs ORY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ORY income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$3.71m |
Earnings | -US$3.70m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.064 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 24.8% |
How did ORY perform over the long term?
See historical performance and comparison